Compare AMPX & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPX | DNLI |
|---|---|---|
| Founded | 2008 | 2013 |
| Country | United States | United States |
| Employees | 109 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 3.0B |
| IPO Year | N/A | 2017 |
| Metric | AMPX | DNLI |
|---|---|---|
| Price | $17.87 | $19.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $20.17 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 8.5M | 1.5M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $76.15 | N/A |
| Revenue Next Year | $59.65 | $408.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.34 | $12.58 |
| 52 Week High | $22.80 | $23.77 |
| Indicator | AMPX | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 46.38 | 49.60 |
| Support Level | $10.00 | $18.86 |
| Resistance Level | $19.76 | $20.35 |
| Average True Range (ATR) | 1.74 | 1.00 |
| MACD | -0.55 | 0.04 |
| Stochastic Oscillator | 33.49 | 62.96 |
Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. Its silicon anodes are a direct drop-in replacement of the graphite anode in traditional lithium-ion batteries, and its manufacturing processes leverage the manufacturing processes for conventional lithium-ion batteries and the related supply chain.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.